HOWL - Werewolf Therapeutics Presents Preliminary Phase 1/1b Clinical Trial Data at SITC Annual Meeting

2023-11-03 08:01:37 ET

DENVER, Colo., Nov 3, 2023 ( www.247marketnews.com )- Werewolf Therapeutics, Inc. (NASDAQ: HOWL) reported, this morning, preliminary first-in-human clinical data from initial monotherapy dose-escalation cohorts in the Company’s lead clinical program, WTX-124×2101, from an ongoing, multi-center Phase 1/1b clinical trial of Werewolf’s interleukin 2 (IL-2) INDUKINE molecule, in patients with advanced or metastatic solid tumors. The preliminary data will be presented today at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting in San Diego, California.

Werewolf Therapeutics is trading at $2.70, up $0.55 (+25.6%), on 176.6K premarket shares traded.

Its 52-week range is $1.39 to $4.5687. Its next resistance point is $2.85.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported …

The post Werewolf Therapeutics Presents Preliminary Phase 1/1b Clinical Trial Data at SITC Annual Meeting appeared first on 24/7 Market News .

For further details see: